Slides
Page 1
June Quarterly Shareholder Update Gary Phillips, CEO ™
Page 2
2 FORWARD LOOKING STATEMENT This document contains forward-looking statements, including statements concerning Syntara’s future financial position, plans, and the potential of its products and product candidates, which are based on information and assumptions available to Syntara as of the date of this document. Actual results, performance or achievements could be significantly different from those expressed in, or implied by, these forward- looking statements. All statements, other than statements of historical facts, are forward-looking statements. These forward-looking statements are not guarantees or predictions of future results, levels of performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results to differ materially from those expressed in the statements contained in this document. For example, despite our efforts there is no certainty that we will be successful in developing or partnering any of the products in our pipeline on commercially acceptable terms, in a timely fashion or at all. Except as required by law we undertake no obligation to update these forward-looking statements as a result of new information, future events or otherwise. 2
Page 3
• Positive US FDA feedback supports the proposed clinical development pathway via Phase 2b trial of amsulostat in myelofibrosis • $8.0 million institutional placement strengthens balance sheet and extends expected cash runway into FY28 • Subsequent to the end of the quarter: − Preliminary Phase 2 SNT-4728 results show a statistically significant reduction in inflammation within a key Parkinson’s disease-related brain region − SNT-9465 Phase 1b hypertrophic scar trial reaches 60% treatment commencement, with recruitment completion targeted for Q3 2026 − AZALOX MDS study advances to final Phase 1b dose cohort • Multiple clinical catalysts expected in H2 2026, including complete SNT-4728 data, amsulostat MDS interim results and SNT-9465 top-line results June Quarter 2026 - Highlights
Page 4
4 SHAREHOLDERS & CASH Financial Information (ASX: SNT) Share price – 23 July 2026 $0.024 Market cap A$47m Cash balance (30 Jun 2026) A$13.5m Enterprise value A$33.5m Institutional Ownership 30 Jun 26 D&A Income Limited 18% Platinum Investment Management Limited 12% Total Institutional Ownership > 44% Share Price & Volume - YTD * 11 August 2025 recorded volume was 119,820,710 following announcement of FDA guidance for amsulostat Research Coverage Canaccord Genuity Euroz Hartleys Bell Potter Evolution Capital 0 0.01 0.02 0.03 0.04 0.05 0.06 0.07 Close 0 5 10 15 20 25 30 Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 Millions Volume
Page 5
5 THREE ASSETS CREATE MULTIPLE PATHS TO VALUE A diversified clinical-stage pipeline across blood cancers, fibrosis and neurodegenerative disease ASSET INDICATION TOTAL ADDRESSABLE MARKET DEVELOPMENT STATUS amsulostat Haematological malignancies Myelofibrosis: ~US$2.8b p.a. Myelodysplastic syndrome: ~US$3.2b p.a. • Phase 2a clinical proof of concept in MF - complete • FDA-aligned planned Phase 2b pathway – Q4 26 start • AZALOX and MESSAGE MDS studies – preliminary data Q4 26 SNT-9465 Fibrosis and skin scarring Global scar-treatment market projected to reach US$50–55b by 2030. • Hypertrophic-scar Phase 1b program – recruiting • Top-line safety and efficacy data targeted in H2 2026. SNT-4728 Parkinson’s disease and iRBD Global Parkinson’s disease market expected to reach US$7.6b by 2030. • Phase 2 iRBD/Parkinson’s program – preliminary data reported • Final study results in Q3 2026.
Page 6
6 * 2024 proposed IWG-ELN criteria Improvements of 50% or more in total symptom score (TSS50) were observed quickly (as early as 12 weeks) and were sustained, with 73% (8/11) of patients achieving TSS50 at Week 24 or beyond Meaningful spleen volume reductions (SVR) were observed at 24 weeks and maintained thereafter, with 44% (4/9) of patients achieving SVR25 at Week 24 or beyond Of the 7 patients that completed 52 weeks of treatment • 6 chose to continue on amsulostat through named patient supply • 3 of these patients had a minor anaemia response • 2 achieved a complete (100%) resolution of symptoms from baseline Differentiated TPP • Competitive safety and efficacy profile in suboptimal MF JAKi patients • Potential for disease modification and use in earlier stage MF • Positive FDA review of Phase 2b trial protocol clears next stage of clinical development 6 Next phase of development and study design for BRIDGE-MF guided by clinical advisory board and aligned with recent FDA feedback. SUMMARY AND NEXT STEPS Top-line Phase 2a data highlights amsulostat’s potential in MF
Page 7
7 Target / Acquiror / / / / / DATE OF ANNOUNCEMENT* JULY-2026 APRIL-2026 MARCH-2026 DEC-2024 FEB-2024 Drug Name Navtemadlin AJ1-11095 Rovadicitinib Elritercept Pelabresib Lead Indication / Phase (at transaction) Myelofibrosis (ongoing Phase 3) Myelofibrosis (ongoing Phase 1) Myelofibrosis (completed Phase 2) MDS and MF (ongoing Phase 2 trials) Myelofibrosis (successful Phase 3 studies) Deal Type Acquisition Acquisition License License Acquisition Upfront / Milestones (US$) US$450M / US$1.3B Total deal value US$2.3B US$135M / US$1.395B US$200M / US$1.1B US$2.9B Earnout Payments / Royalty Rate (%) Not disclosed Not disclosed Not disclosed Not disclosed Subject to regulatory approvals Attractive commercial outcomes for drugs with Phase 2 and 3 data expected to drive interest in amsulostat Phase 2 data STRONG INTEREST IN MF ASSETS FROM STRATEGICS * Prior to 2024: SOBI acquisition of Pacritinib from CTI for US$1.7B GSK acquisition of Momelotinib from Sierra Oncology for US$1.9B
Page 8
8 Ideal add-on for patients with sub-optimal response to JAKi • FDA endorsed phase 2b protocol • Pan-lysyl oxidase inhibition mechanism and favourable tolerability support combination use with JAKi. • Inhibition of LOX-mediated PDGFR signalling enhances impact of JAKi on cell proliferation. • Potential to improve symptoms and extend the useful treatment duration of JAKi through effects on the bone marrow microenvironment. AMSULOSTAT: A NEW FUTURE IN MF TREATMENT OPTIONS Potentially best positioned in frontline combination with JAKi • Pan-lysyl oxidase inhibition mechanism and favourable tolerability profile makes amsulostat well suited for early combination use. • Targeting fibrosis biology and microenvironmental signaling complements JAK inhibition. • Early use maximises impact on symptoms, spleen response and longer-term disease biology. 8 Opportunity to slow progression in newly diagnosed MF • Pan-lysyl oxidase inhibition may preserve and restore the bone microenvironment to slow disease progression. • Strong tolerability supports use earlier in treatment paradigm, before patients become symptomatic. • Potential for disease modification and improved survival is maximised when used early. Aspirational lifecycle development in MF enabled by first in class pan-LOX mechanism Market Opportunity ~$1b Market Opportunity ~$1.8b Market Opportunity ~$2.8b
Page 9
9 Baseline Week 12 -0.2 -0.1 0.0 0.1 0.2 BPND ✱p<0.05 Placebo SNT-4728 -0.10 -0.05 0.00 0.05 Δ BPND ✱p<0.05 REDUCTION IN INFLAMMATION Statistically significant reduction in brain inflammation observed unilaterally in the putamen (p-value 0.0145) • The putamen is a key region underlying the hallmark motor symptoms of Parkinson’s disease. • 20 out of 30 pts on active treatment (SNT- 4728) recorded a reduction in inflammation from baseline. • No statistically significant change in inflammation was detected in other predefined regions of interest. • No significant reduction in brain inflammation in any region for placebo group. Putamen Binding Potential (BPND) Mean change P-value (Paired t- test)Mean at baseline Mean at 12 weeks Right 0.002918 -0.012073 -0.016 (0.033) 0.0145 Left -0.001209 0.001692 0.003 (0.029) 0.6219 BPND is a dimensionless number expressing the distribution volume ratio of specifically bound radioligand to that of non-displaceable radioligand. 20/30 pts had reduced inflammation after 12 weeks treatment. At week 12, inflammation significantly reduced compared to placebo.
Page 10
10 INNOVATIVE TRIAL DESIGN TO EVALUATE COMMERCIAL VIABILITY Randomized, Double-blinded, Placebo-controlled Split-scar Study in Adult Participants with Hypertrophic Sternotomy Scars (N=20) Hypertrophic scars Phase 1b Multiple Daily Dose Trial design optimised for inclusion criteria and endpoints PRIMARY ENDPOINT ▪ Safety TEAEs SECONDARY ENDPOINTS ▪ Pharmacokinetics / Pharmacodynamics ▪ Scar rating (multiple blinded raters) ▪ 3D imaging (scar volume) ▪ Optical Coherence Tomography (OCT) ▪ Elastography ▪ Patient and Observer Scar Assessment Scale (POSAS) Placebo controlled scar remodeling study with multiple efficacy readouts in H2 2026 Healthy Volunteer Phase 1a Single Ascending Dose ✓ Dose-dependent target engagement confirmed
Page 11
TARGET DRUG INDICATION PARTNERS PHASE 1 PHASE 2 ANTICIPATED NEWS FLOW HEALTHY PARTICIPANTS PATIENTS H1 2026 H2 2026 Pan-LOX Amsulostat (SNT-5505) Myelofibrosis FDA approved development plan and partner engagement Trial Progression High Risk MDS AZALOX trial Interim safety and efficacy data Phase 2 initiation Low / Int Risk MDS MESSAGE trial Interim safety and efficacy data Pancreatic cancer FALCON trial Investigator Study TBD Topical Pan-LOX SNT-9465 Hypertrophic scarring Recruit hypertrophic scar Phase 1b trial Top Line safety and efficacy data SNT-6302 Keloid scarring Interim safety and efficacy data Dual SSAO & MAO-B SNT-4728 IRBD / Parkinson’s Disease Phase 2 Top Line data Phase 2 full results THE YEAR AHEAD - POISED TO DELIVER NEAR TERM VALUE MDS: Myelodysplastic Syndrome; Int: Intermediate; IRBD: Isolated REM sleep Behaviour Disorder 11
Page 12
Gary Phillips Chief Executive Officer gary.phillips@syntaratx.com.au Alison Findlay Head Business Development & Licensing alison.findlay@syntaratx.com.auhttp://syntaratx.com.au